Search - tctmd.com

Displaying 21 - 40 of 432

Sort: Relevancy | Date

News Daily News

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

Michael O'Riordan

November 20, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

News Daily News

Impact of On-site Cardiac Surgery on Clinical Outcomes After Transfemoral TAVR

Michael O'Riordan

November 09, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

L.A. McKeown

November 08, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA: Contaminated Irbesartan Now Under Voluntary Recall

Michael O'Riordan

October 31, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Features

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Michael O'Riordan

October 29, 2018

Advertisement

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

Impact of On-site Cardiac Surgery on Clinical Outcomes After Transfemoral TAVR

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA: Contaminated Irbesartan Now Under Voluntary Recall

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content